We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Japan-based Chugai Pharmaceutical has revealed plans to expand its research subsidiary in Singapore, Chugai Pharmabody Research (CPR), in order to enhance its drug discovery capabilities.